MX391156B - Forma polimorfica de sepiapterina. - Google Patents

Forma polimorfica de sepiapterina.

Info

Publication number
MX391156B
MX391156B MX2019006207A MX2019006207A MX391156B MX 391156 B MX391156 B MX 391156B MX 2019006207 A MX2019006207 A MX 2019006207A MX 2019006207 A MX2019006207 A MX 2019006207A MX 391156 B MX391156 B MX 391156B
Authority
MX
Mexico
Prior art keywords
crystalline form
sepiapterina
polymorphic form
sepiapterin
dysfunction
Prior art date
Application number
MX2019006207A
Other languages
English (en)
Spanish (es)
Other versions
MX2019006207A (es
Inventor
Daniel E Levy
Hiroshi Yoshino
Kaito Kishimoto
Shunichi Murata
Taichi Komoda
Takayoshi Matsumoto
Yuichi Shiro
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2019006207A publication Critical patent/MX2019006207A/es
Publication of MX391156B publication Critical patent/MX391156B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019006207A 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina. MX391156B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
PCT/US2017/063515 WO2018102314A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Publications (2)

Publication Number Publication Date
MX2019006207A MX2019006207A (es) 2019-11-18
MX391156B true MX391156B (es) 2025-03-21

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006207A MX391156B (es) 2016-11-29 2017-11-28 Forma polimorfica de sepiapterina.

Country Status (8)

Country Link
US (2) US11130760B2 (enExample)
EP (1) EP3548487A4 (enExample)
JP (1) JP7148532B2 (enExample)
CN (1) CN110312721A (enExample)
CA (1) CA3043499A1 (enExample)
MA (1) MA46972A (enExample)
MX (1) MX391156B (enExample)
WO (1) WO2018102314A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
AU2021209935A1 (en) 2020-01-24 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating Parkinson's disease with sepiapterin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
WO2023055923A1 (en) * 2021-09-29 2023-04-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
CN117117299B (zh) * 2023-08-14 2024-12-06 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005041975A1 (en) 2003-10-31 2005-05-12 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
JP2007536210A (ja) 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
HUE029533T2 (en) 2003-11-17 2017-03-28 Biomarin Pharm Inc Treatment of phenylketonuria with BH4
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
DK3461503T3 (da) 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
NZ588379A (en) 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2680848A4 (en) 2011-03-01 2014-11-05 Rubicon Res Private Ltd STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
ES2681345T3 (es) * 2012-05-07 2018-09-12 Shiratori Pharmaceutical Co., Ltd. Método para producir sepiapterina y tetrahidrolactoilpterina
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
JP2019527242A (ja) 2016-07-29 2019-09-26 ディファーマ エッセ．ア． サプロプテリンジヒドロクロリドを含む医薬組成物キット
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법

Also Published As

Publication number Publication date
US20200010469A1 (en) 2020-01-09
US20220081443A1 (en) 2022-03-17
WO2018102314A1 (en) 2018-06-07
MA46972A (fr) 2019-10-09
CA3043499A1 (en) 2018-06-07
JP7148532B2 (ja) 2022-10-05
US12325706B2 (en) 2025-06-10
US11130760B2 (en) 2021-09-28
EP3548487A1 (en) 2019-10-09
EP3548487A4 (en) 2020-04-29
JP2020500931A (ja) 2020-01-16
CN110312721A (zh) 2019-10-08
MX2019006207A (es) 2019-11-18

Similar Documents

Publication Publication Date Title
MX391156B (es) Forma polimorfica de sepiapterina.
EA201790693A1 (ru) Коррекция фигуры
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX393057B (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
MX382520B (es) Compuestos de pirimidinodiona contra estados cardiacos.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
TN2017000158A1 (en) Carbazole derivatives
NZ757929A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PH12016502353A1 (en) Pharmaceutical composition
MX390051B (es) Antagonistas de ep4.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
PH12016502352A1 (en) Pharmaceutical composition
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений